Search PubMed⌕ Search

Biomedical subjects

P Krupp

Publications and source records attributed to P Krupp.

At least 37 records · Page 2Linked to original sources
PubMed1989

The risk of neoplasms in patients treated with cyclosporine A.

Immunosuppressive therapy (IT) carries inherent risks involving the occurrence of lymphoproliferative disorders and malignancies (MA). The most frequently observed neoplasms in organ-transplant (OT) recipients treated with cyclosporine A (Cy-A) involve the skin and the lympho-reticular system. A disproportionally high percentage of the skin MA are Kaposi's sarcoma. Compared with a normal, not-exposed population matched for age, sex and country; Cy-A-treated OT recipients have a 28-times higher prevalence of lymphomas. This figure compares with a 34 to 59-fold increased risk in patients receiving conventional immunosuppressive therapy (CIT) for OT. However, it appears that in Cy-A-treated patients the latency period for the development of lymphomas is shorter than in patients on CIT. Other MA are increased seven-fold in Cy-A-treated patients and between two- and six-fold in those receiving CIT. The overall incidence of all types of MA is increased two-fold for Cy-A recipients and between two- and four-fold for those on CIT. Therefore patients receiving IT should be carefully monitored with respect to the possible occurrence of neoplasms.

Autoimmune Diseases↗
PubMed1987

Bromocriptine in pregnancy: safety aspects.

Since Bromocriptine is used to restore fertility in hyperprolactinemic women, its safety in pregnancy and the offspring was investigated in a stepwise approach: (i) the first survey in pregnancy was based on spontaneous reporting, (ii) the second investigation was conducted at 33 clinics as an intensive monitoring project and, (iii) the third study consisted in a full examination of children up to the age of 9 years who had been exposed to Bromocriptine in utero. The data collated in this program includes information on 2587 pregnancies in 2437 women treated with Bromocriptine during some stage of gestation, and follow-up examinations for 988 infants. The results show that the use of Bromocriptine in the treatment of infertility in women is not associated with an increased risk of spontaneous abortion, multiple pregnancy or the occurrence of congenital malformation in their progeny. Moreover, exposure to this drug in utero has no adverse influence on the postnatal development.

Abnormalities, Drug-Induced↗
PubMed1986

Co-dergocrine.

Explore the source record for details and available documents.

Dihydroergotoxine↗
PubMed1982

Surveillance of bromocriptine in pregnancy.

Information was collected on the outcome of 1,410 pregnancies in 1,335 women to whom bromocriptine mesylate (Parlodel) had been given, primarily in the early weeks of pregnancy. These Pregnancies resulted in 197 early terminations (14%) (including 25 induced abortions [1.8%) and in 1,213 births (86%). The incidence rate of spontaneous abortions (11.1%), extrauterine pregnancies (0.9%), and minor (2.5%) and major (1.0%) malformations is comparable with that quoted for normal populations, and the incidence of twin pregnancies (1.8%) is slightly but not significantly raised, if correction is made for concomitant therapy with other agents inducing ovulation. The data suggest that the intake of bromocriptine during pregnancy is not associated with an increased risk to the fetus.

Abnormalities, Drug-Induced↗
PubMed1982

Pindolol: experience gained in 10 years of safety monitoring.

The benefit to be expected from any drug therapy should outweigh its inherent risk. All adverse events reported in connection with administration of pindolol have been carefully analyzed since this drug was marketed 10 years ago. The investigation included the data published in the literature, the information provided by spontaneous reporting or by bulletins issued by various national drug evaluation committees, and the results obtained by intensive hospital monitoring. This international surveillance reveals that pindolol elicits adverse reactions related to beta-adrenoceptor blockade; however, the incidence and especially the intensity of this type of side effect appear to be attenuated by the intrinsic sympathomimetic property exhibited by pindolol. Some other reported side effects, in general equally mild, cannot be explained by the known pharmacodynamic properties of pindolol. However, no specific toxicity has been observed even after long-term treatment. Taking into consideration that pindolol has been used for more than 3.7 million patient-years, it is certainly justified to assume that the full spectrum of adverse reactions that might be induced by this drug has been recognized and that in all probability no severe new untoward effects will be observed in the future.

Clinical Trials as Topic↗